Cavo, M
Pantani, L
Pezzi, A
Petrucci, M T
Patriarca, F
Di Raimondo, F
Marzocchi, G
Galli, M
Montefusco, V
Zamagni, E
Gamberi, B
Tacchetti, P
Brioli, A
Palumbo, A
Sonneveld, P
Article History
First Online: 7 October 2015
Competing interests
: MC has received honoraria from Janssen, Celgene, Amgen, Bristol–Myers Squibb and Millennium Pharmaceuticals; has served on speakers' bureaux for Janssen and Celgene; has been a consultant for Janssen, Celgene, Amgen and Millennium. MTP has received honoraria from Janssen and Celgene. FP has received honoraria from Janssen and Celgene. FDR has received honoraria and served on speakers’ bureaux for Celgene and Janssen. EZ has received honoraria from Janssen and Celgene. AP has received honoraria from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Merck and Millennium; has been a consultant for Celgene, Janssen, Amgen, Bristol–Myers Squibb and Millennium. PS has received research support and honoraria from Celgene, Janssen, Onyx and Millennium. All other authors declare that they have no conflicts of interest.